Stockscreener 앱 받기
18.46
1.71%
0.31
전일 마감가:
$18.15
열려 있는:
$17.98
하루 거래량:
1.39M
Relative Volume:
0.68
시가총액:
$2.63B
수익:
-
순이익/손실:
$-45.61M
주가수익비율:
-57.06
EPS:
-0.3235
순현금흐름:
$-45.40M
1주 성능:
-0.27%
1개월 성능:
+3.07%
6개월 성능:
+77.50%
1년 성능:
+146.46%
1일 변동 폭
$17.63
$18.54
1주일 범위
$17.52
$18.84
52주 변동 폭
$6.93
$20.22
트레비 테라퓨틱스 Stock (TRVI) Company Profile
명칭
Trevi Therapeutics Inc
전화
203-304-2499
주소
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
18.46 | 2.53B | 0 | -45.61M | -45.40M | -0.3235 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
트레비 테라퓨틱스 Stock (TRVI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-13 | 개시 | Leerink Partners | Outperform |
| 2025-08-21 | 개시 | Morgan Stanley | Overweight |
| 2025-07-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-05-28 | 개시 | H.C. Wainwright | Buy |
| 2025-03-10 | 재확인 | Needham | Buy |
| 2025-03-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-30 | 개시 | Raymond James | Outperform |
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2023-04-12 | 개시 | B. Riley Securities | Buy |
| 2022-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-06-03 | 개시 | BMO Capital Markets | Outperform |
| 2019-06-03 | 개시 | Needham | Buy |
| 2019-06-03 | 개시 | SVB Leerink | Outperform |
| 2019-06-03 | 개시 | Stifel | Buy |
모두보기
트레비 테라퓨틱스 주식(TRVI)의 최신 뉴스
TRVI Maintained by Jones Trading -- Price Target Raised to $28.0 - GuruFocus
JonesTrading Forecasts Strong Price Appreciation for Trevi Therapeutics (NASDAQ:TRVI) Stock - MarketBeat
Does Wider Losses And New US$149.2m Shelf Offering Change The Bull Case For Trevi (TRVI)? - simplywall.st
HC Wainwright Issues Pessimistic Estimate for TRVI Earnings - MarketBeat
Sei Investments Co. Has $933,000 Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
What is HC Wainwright's Forecast for TRVI FY2030 Earnings? - MarketBeat
H.C. Wainwright Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Morgan Stanley Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $23 - Moomoo
1,525,314 Shares in Trevi Therapeutics, Inc. $TRVI Acquired by Assenagon Asset Management S.A. - MarketBeat
A Quick Look at Today's Ratings for Trevi Therapeutics(TRVI.US), With a Forecast Between $23 to $40 - Moomoo
Raymond James Sticks to Its Buy Rating for Trevi Therapeutics (TRVI) - The Globe and Mail
Trevi Therapeutics (TRVI) Receives a New Rating from B. Riley Securities - The Globe and Mail
Q2 2026 Trevi Therapeutics Inc Earnings Call Transcript - GuruFocus
Oppenheimer Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $25 - Moomoo
Morgan Stanley Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $23 - Moomoo
Trevi Therapeutics (NASDAQ:TRVI) Announces Earnings Results, Hits Estimates - MarketBeat
Trevi Therapeutics Q2 Earnings Call Highlights - MarketBeat
Trevi Therapeutics, Inc. Stock 12‑Month Price Target Raised to $29.17, Implies 58% Upside - TradingView
Trevi Therapeutics Inc (TRVI) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
TRVI Maintains Rating by Oppenheimer -- Price Target Raised to $25.00 - GuruFocus
TRVI Maintains Overweight Rating -- Price Target Raised to $30 b - GuruFocus
Oppenheimer Adjusts Trevi Therapeutics PT to $25 From $24, Maintains Outperform Rating - marketscreener.com
TREVI THERAPEUTICS, INC. : OPPENHEIMER RAISES TARGET PRICE TO $25 FROM $24 - Bitget
Cantor Fitzgerald Forecasts Strong Price Appreciation for Trevi Therapeutics (NASDAQ:TRVI) Stock - MarketBeat
Raymond James raises Trevi Therapeutics price target on pipeline progress By Investing.com - Investing.com Australia
TRVI SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Trevi Therapeutics Inc (TRVI) (Q2 2026) Earnings Call Highlights - GuruFocus
Earnings call transcript: Trevi Therapeutics posts small Q2 2026 EPS miss - Investing.com UK
Trevi Therapeutics Inc (TRVI) (Q2 2026) Earnings Call Highlights: Advancing Phase 3 Pipeline ... - Yahoo Finance
Trevi Therapeutics (TRVI) Advances Clinical Trials Amid High Val - GuruFocus
Trevi Therapeutics : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q) - marketscreener.com
Trevi Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Trevi Q2 2026 Earnings: Higher Trial Spending Widens the Net Loss - TradingKey
Trevi Therapeutics, Inc. 2Q 2026: Net loss $17.8M, EPS $(0.11) — 10-Q Summary - TradingView
Trevi Therapeutics Q2 net loss widens on higher R&D costs - TradingView
Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Trevi Therapeutics (NASDAQ: TRVI) funds late-stage cough trials with $318.9M - Stock Titan
Trevi Therapeutics reports Q2 2026 net loss of $17.8M; $318.9M cash and marketable securities - TradingView
Trevi Therapeutics faces earnings test as Haduvio trials advance By Investing.com - Investing.com Nigeria
Trevi Therapeutics faces earnings test as Haduvio trials advance - Investing.com
FMR LLC discloses 8.8% Trevi Therapeutics (TRVI) ownership in amended 13G - Stock Titan
$Trevi Therapeutics (TRVI.US)$ squeeze baby squeeze - Moomoo
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Average Rating of "Buy" from Analysts - MarketBeat
Trevi Therapeutics sets Aug. 6 update on chronic-cough therapy - Stock Titan
Trevi Therapeutics (TRVI) to Post Earnings on Thursday - MarketBeat
Trevi Therapeutics to present at August biotech conferences on its chronic cough therapy Haduvio™ - Pluang
Trevi Therapeutics to Participate in Upcoming August Conferences - Yahoo Finance
Trevi's CEO and CFO join August biotech events in two states - Stock Titan
Trevi Therapeutics, Inc. Revenue Breakdown – NASDAQ:TRVI - TradingView
Trevi Therapeutics, Inc. $TRVI Shares Sold by Orbimed Advisors LLC - MarketBeat
Octagon Capital Advisors LP Reduces Stock Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
트레비 테라퓨틱스 (TRVI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):